Cargando…

Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life

Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs”. The primary goal of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Farooq, Juveriya, Sana, M.M., Chetana, P.M., Almuqbil, Mansour, Prabhakar Bhat, Nagapati, Sultana, Rokeya, Khaiser, UmaimaFarheen, Mohammed Basheeruddin Asdaq, Syed, Almalki, Mutlaq Eidhah M., Mohammed sawadi Khormi, Amro, Ahmad Albraiki, Salem, Almadani, Moneer E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415215/
https://www.ncbi.nlm.nih.gov/pubmed/37576859
http://dx.doi.org/10.1016/j.jsps.2023.06.001
_version_ 1785087478226485248
author Farooq, Juveriya
Sana, M.M.
Chetana, P.M.
Almuqbil, Mansour
Prabhakar Bhat, Nagapati
Sultana, Rokeya
Khaiser, UmaimaFarheen
Mohammed Basheeruddin Asdaq, Syed
Almalki, Mutlaq Eidhah M.
Mohammed sawadi Khormi, Amro
Ahmad Albraiki, Salem
Almadani, Moneer E.
author_facet Farooq, Juveriya
Sana, M.M.
Chetana, P.M.
Almuqbil, Mansour
Prabhakar Bhat, Nagapati
Sultana, Rokeya
Khaiser, UmaimaFarheen
Mohammed Basheeruddin Asdaq, Syed
Almalki, Mutlaq Eidhah M.
Mohammed sawadi Khormi, Amro
Ahmad Albraiki, Salem
Almadani, Moneer E.
author_sort Farooq, Juveriya
collection PubMed
description Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs”. The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety.
format Online
Article
Text
id pubmed-10415215
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104152152023-08-12 Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life Farooq, Juveriya Sana, M.M. Chetana, P.M. Almuqbil, Mansour Prabhakar Bhat, Nagapati Sultana, Rokeya Khaiser, UmaimaFarheen Mohammed Basheeruddin Asdaq, Syed Almalki, Mutlaq Eidhah M. Mohammed sawadi Khormi, Amro Ahmad Albraiki, Salem Almadani, Moneer E. Saudi Pharm J Original Article Multiple prescriptions for different medications may be needed for chronic conditions, increasing the risk of polypharmacy. The WHO defined polypharmacy as “the administration of many drugs at the same time or the administration of an excessive number of drugs”. The primary goal of this study was to evaluate polypharmacy in patients with chronic liver disease and to identify potential drug-drug interactions associated with it. A cross-sectional study was conducted at a tertiary care hospital in Mangalore, Karnataka, for six months, from November 2020 to April 2021. The study involved 118 patients with chronic liver disease from various age groups. Data was gathered by analyzing patients' medical records kept on the ward and interviewing them individually. In admission and discharge prescriptions, polypharmacy was examined. Online interaction checkers from Drugs.com and Medscape were used to interpret potential drug-drug interactions. The SF-36 and Chronic Liver Disease Questionnaire were used to measure the quality of life. The data obtained were analyzed statistically to determine the significant correlation. The number of prescribed drugs was significantly correlated (P = 0.018) with the severity of liver disease in Child-Pugh categories B and C. Additionally, moderate polypharmacy reduced quality of life (P < 0.05), and the physical health category was significantly associated with disease severity (P < 0.05). Drug-drug interactions were found in 108 out of the 118 examined prescriptions, totaling 586 interactions in the admission list and 405 interactions in the discharge list. If the potentially serious main drug interaction identified in this study is not well monitored, it could lead to a serious, potentially fatal health condition. Despite being advised, safety is not always guaranteed by liver enzyme monitoring. Therefore, healthcare providers must take additional precautions to avoid inappropriate prescribing, minimize side effects, and ensure drug safety. Elsevier 2023-08 2023-06-09 /pmc/articles/PMC10415215/ /pubmed/37576859 http://dx.doi.org/10.1016/j.jsps.2023.06.001 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Farooq, Juveriya
Sana, M.M.
Chetana, P.M.
Almuqbil, Mansour
Prabhakar Bhat, Nagapati
Sultana, Rokeya
Khaiser, UmaimaFarheen
Mohammed Basheeruddin Asdaq, Syed
Almalki, Mutlaq Eidhah M.
Mohammed sawadi Khormi, Amro
Ahmad Albraiki, Salem
Almadani, Moneer E.
Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
title Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
title_full Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
title_fullStr Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
title_full_unstemmed Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
title_short Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
title_sort polypharmacy in chronic liver disease patients: implications for disease severity, drug-drug interaction, and quality of life
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415215/
https://www.ncbi.nlm.nih.gov/pubmed/37576859
http://dx.doi.org/10.1016/j.jsps.2023.06.001
work_keys_str_mv AT farooqjuveriya polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT sanamm polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT chetanapm polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT almuqbilmansour polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT prabhakarbhatnagapati polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT sultanarokeya polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT khaiserumaimafarheen polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT mohammedbasheeruddinasdaqsyed polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT almalkimutlaqeidhahm polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT mohammedsawadikhormiamro polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT ahmadalbraikisalem polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife
AT almadanimoneere polypharmacyinchronicliverdiseasepatientsimplicationsfordiseaseseveritydrugdruginteractionandqualityoflife